Product Sales year-on-year analysis: H1 2026 (Details) - USD ($)
$ in Millions |
3 Months Ended |
6 Months Ended |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
| Product sales |
|
|
|
|
| Product Sales |
$ 14,510
|
$ 13,795
|
$ 28,896
|
$ 26,670
|
| Actual %, year-on-year |
5.00%
|
|
8.00%
|
|
| CER %, year-on-year |
4.00%
|
|
5.00%
|
|
| US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 6,026
|
|
$ 11,704
|
|
| Actual %, year-on-year |
3.00%
|
|
6.00%
|
|
| Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 3,860
|
|
$ 8,178
|
|
| Actual %, year-on-year |
4.00%
|
|
8.00%
|
|
| CER %, year-on-year |
|
|
3.00%
|
|
| Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 3,280
|
|
$ 6,487
|
|
| Actual %, year-on-year |
11.00%
|
|
16.00%
|
|
| CER %, year-on-year |
7.00%
|
|
7.00%
|
|
| Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,344
|
|
$ 2,527
|
|
| Actual %, year-on-year |
4.00%
|
|
4.00%
|
|
| CER %, year-on-year |
9.00%
|
|
6.00%
|
|
| Total Oncology |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 6,713
|
|
$ 12,948
|
|
| Actual %, year-on-year |
15.00%
|
|
17.00%
|
|
| CER %, year-on-year |
13.00%
|
|
14.00%
|
|
| Total Oncology | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 3,163
|
|
$ 5,951
|
|
| Actual %, year-on-year |
14.00%
|
|
15.00%
|
|
| Total Oncology | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,522
|
|
$ 3,043
|
|
| Actual %, year-on-year |
16.00%
|
|
16.00%
|
|
| CER %, year-on-year |
12.00%
|
|
11.00%
|
|
| Total Oncology | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,408
|
|
$ 2,786
|
|
| Actual %, year-on-year |
19.00%
|
|
26.00%
|
|
| CER %, year-on-year |
14.00%
|
|
16.00%
|
|
| Total Oncology | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 620
|
|
$ 1,168
|
|
| Actual %, year-on-year |
5.00%
|
|
9.00%
|
|
| CER %, year-on-year |
10.00%
|
|
11.00%
|
|
| Tagrisso |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,941
|
|
$ 3,775
|
|
| Actual %, year-on-year |
7.00%
|
|
8.00%
|
|
| CER %, year-on-year |
6.00%
|
|
6.00%
|
|
| Tagrisso | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 845
|
|
$ 1,579
|
|
| Actual %, year-on-year |
11.00%
|
|
10.00%
|
|
| Tagrisso | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 512
|
|
$ 1,048
|
|
| Actual %, year-on-year |
5.00%
|
|
4.00%
|
|
| CER %, year-on-year |
1.00%
|
|
|
|
| Tagrisso | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 383
|
|
$ 769
|
|
| Actual %, year-on-year |
9.00%
|
|
17.00%
|
|
| CER %, year-on-year |
4.00%
|
|
8.00%
|
|
| Tagrisso | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 201
|
|
$ 379
|
|
| Actual %, year-on-year |
(3.00%)
|
|
(1.00%)
|
|
| CER %, year-on-year |
2.00%
|
|
2.00%
|
|
| Imfinzi |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,854
|
|
$ 3,548
|
|
| Actual %, year-on-year |
27.00%
|
|
31.00%
|
|
| CER %, year-on-year |
27.00%
|
|
29.00%
|
|
| Imfinzi | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,054
|
|
$ 2,008
|
|
| Actual %, year-on-year |
25.00%
|
|
28.00%
|
|
| Imfinzi | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 211
|
|
$ 398
|
|
| Actual %, year-on-year |
39.00%
|
|
35.00%
|
|
| CER %, year-on-year |
36.00%
|
|
32.00%
|
|
| Imfinzi | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 398
|
|
$ 781
|
|
| Actual %, year-on-year |
39.00%
|
|
45.00%
|
|
| CER %, year-on-year |
34.00%
|
|
34.00%
|
|
| Imfinzi | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 191
|
|
$ 361
|
|
| Actual %, year-on-year |
10.00%
|
|
15.00%
|
|
| CER %, year-on-year |
17.00%
|
|
20.00%
|
|
| Calquence |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,022
|
|
$ 1,944
|
|
| Actual %, year-on-year |
17.00%
|
|
19.00%
|
|
| CER %, year-on-year |
16.00%
|
|
16.00%
|
|
| Calquence | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 687
|
|
$ 1,286
|
|
| Actual %, year-on-year |
18.00%
|
|
18.00%
|
|
| Calquence | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 67
|
|
$ 137
|
|
| Actual %, year-on-year |
36.00%
|
|
33.00%
|
|
| CER %, year-on-year |
30.00%
|
|
26.00%
|
|
| Calquence | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 225
|
|
$ 442
|
|
| Actual %, year-on-year |
13.00%
|
|
20.00%
|
|
| CER %, year-on-year |
9.00%
|
|
11.00%
|
|
| Calquence | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 43
|
|
$ 79
|
|
| Actual %, year-on-year |
3.00%
|
|
9.00%
|
|
| CER %, year-on-year |
3.00%
|
|
7.00%
|
|
| Lynparza |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 829
|
|
$ 1,610
|
|
| Actual %, year-on-year |
(1.00%)
|
|
3.00%
|
|
| CER %, year-on-year |
(3.00%)
|
|
(1.00%)
|
|
| Lynparza | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 351
|
|
$ 659
|
|
| Actual %, year-on-year |
(7.00%)
|
|
(4.00%)
|
|
| Lynparza | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 170
|
|
$ 343
|
|
| Actual %, year-on-year |
4.00%
|
|
6.00%
|
|
| CER %, year-on-year |
(2.00%)
|
|
(1.00%)
|
|
| Lynparza | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 240
|
|
$ 480
|
|
| Actual %, year-on-year |
5.00%
|
|
13.00%
|
|
| CER %, year-on-year |
1.00%
|
|
4.00%
|
|
| Lynparza | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 68
|
|
$ 128
|
|
| Actual %, year-on-year |
(2.00%)
|
|
1.00%
|
|
| CER %, year-on-year |
3.00%
|
|
3.00%
|
|
| Enhertu |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 338
|
|
$ 662
|
|
| Actual %, year-on-year |
47.00%
|
|
55.00%
|
|
| CER %, year-on-year |
44.00%
|
|
49.00%
|
|
| Enhertu | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 223
|
|
$ 440
|
|
| Actual %, year-on-year |
43.00%
|
|
51.00%
|
|
| CER %, year-on-year |
41.00%
|
|
47.00%
|
|
| Enhertu | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 68
|
|
$ 132
|
|
| Actual %, year-on-year |
34.00%
|
|
41.00%
|
|
| CER %, year-on-year |
28.00%
|
|
28.00%
|
|
| Enhertu | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 47
|
|
$ 90
|
|
| CER %, year-on-year |
98.00%
|
|
|
|
| Zoladex |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 304
|
|
$ 607
|
|
| Actual %, year-on-year |
7.00%
|
|
7.00%
|
|
| CER %, year-on-year |
2.00%
|
|
2.00%
|
|
| Zoladex | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 5
|
|
$ 9
|
|
| Actual %, year-on-year |
10.00%
|
|
4.00%
|
|
| Zoladex | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 239
|
|
$ 480
|
|
| Actual %, year-on-year |
9.00%
|
|
9.00%
|
|
| CER %, year-on-year |
4.00%
|
|
4.00%
|
|
| Zoladex | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 42
|
|
$ 81
|
|
| Actual %, year-on-year |
10.00%
|
|
13.00%
|
|
| CER %, year-on-year |
5.00%
|
|
5.00%
|
|
| Zoladex | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 18
|
|
$ 37
|
|
| Actual %, year-on-year |
(23.00%)
|
|
(16.00%)
|
|
| CER %, year-on-year |
(24.00%)
|
|
(18.00%)
|
|
| Truqap |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 233
|
|
$ 431
|
|
| Actual %, year-on-year |
37.00%
|
|
43.00%
|
|
| CER %, year-on-year |
37.00%
|
|
41.00%
|
|
| Truqap | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 168
|
|
$ 306
|
|
| Actual %, year-on-year |
18.00%
|
|
21.00%
|
|
| Truqap | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 17
|
|
$ 35
|
|
| Truqap | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
34
|
|
65
|
|
| Truqap | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 14
|
|
$ 25
|
|
| Actual %, year-on-year |
77.00%
|
|
98.00%
|
|
| CER %, year-on-year |
85.00%
|
|
|
|
| Imjudo |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 83
|
|
$ 160
|
|
| Actual %, year-on-year |
(7.00%)
|
|
(6.00%)
|
|
| CER %, year-on-year |
(7.00%)
|
|
(7.00%)
|
|
| Imjudo | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 51
|
|
$ 100
|
|
| Actual %, year-on-year |
(11.00%)
|
|
10.00%
|
|
| Imjudo | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 7
|
|
$ 13
|
|
| Actual %, year-on-year |
(3.00%)
|
|
9.00%
|
|
| CER %, year-on-year |
(3.00%)
|
|
8.00%
|
|
| Imjudo | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 14
|
|
$ 28
|
|
| Actual %, year-on-year |
25.00%
|
|
22.00%
|
|
| CER %, year-on-year |
20.00%
|
|
13.00%
|
|
| Imjudo | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 11
|
|
$ 19
|
|
| Actual %, year-on-year |
(21.00%)
|
|
(22.00%)
|
|
| CER %, year-on-year |
(16.00%)
|
|
(19.00%)
|
|
| Datroway |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 4
|
|
$ 5
|
|
| Datroway | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
4
|
|
5
|
|
| Etcamah |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
3
|
|
3
|
|
| Etcamah | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
3
|
|
3
|
|
| Other Oncology |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 102
|
|
$ 203
|
|
| Actual %, year-on-year |
(4.00%)
|
|
(6.00%)
|
|
| CER %, year-on-year |
(5.00%)
|
|
(8.00%)
|
|
| Other Oncology | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 2
|
|
$ 4
|
|
| Actual %, year-on-year |
58.00%
|
|
(1.00%)
|
|
| Other Oncology | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 69
|
|
$ 141
|
|
| Actual %, year-on-year |
(2.00%)
|
|
(3.00%)
|
|
| CER %, year-on-year |
(5.00%)
|
|
(6.00%)
|
|
| Other Oncology | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 4
|
|
$ 8
|
|
| Actual %, year-on-year |
(15.00%)
|
|
(19.00%)
|
|
| CER %, year-on-year |
(28.00%)
|
|
(30.00%)
|
|
| Other Oncology | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 27
|
|
$ 50
|
|
| Actual %, year-on-year |
(11.00%)
|
|
(12.00%)
|
|
| CER %, year-on-year |
(3.00%)
|
|
(7.00%)
|
|
| BioPharmaceuticals: total CVRM |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 2,771
|
|
$ 6,011
|
|
| Actual %, year-on-year |
(15.00%)
|
|
(8.00%)
|
|
| CER %, year-on-year |
(18.00%)
|
|
(12.00%)
|
|
| BioPharmaceuticals: total CVRM | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 375
|
|
$ 968
|
|
| Actual %, year-on-year |
(44.00%)
|
|
(28.00%)
|
|
| BioPharmaceuticals: total CVRM | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,346
|
|
$ 2,998
|
|
| Actual %, year-on-year |
(11.00%)
|
|
(2.00%)
|
|
| CER %, year-on-year |
(15.00%)
|
|
(7.00%)
|
|
| BioPharmaceuticals: total CVRM | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 887
|
|
$ 1,756
|
|
| Actual %, year-on-year |
|
|
3.00%
|
|
| CER %, year-on-year |
(4.00%)
|
|
(5.00%)
|
|
| BioPharmaceuticals: total CVRM | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 163
|
|
$ 289
|
|
| Actual %, year-on-year |
(16.00%)
|
|
(27.00%)
|
|
| CER %, year-on-year |
(12.00%)
|
|
(25.00%)
|
|
| Farxiga |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,804
|
|
$ 3,997
|
|
| Actual %, year-on-year |
(16.00%)
|
|
(5.00%)
|
|
| CER %, year-on-year |
(19.00%)
|
|
(11.00%)
|
|
| Farxiga | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 219
|
|
$ 668
|
|
| Actual %, year-on-year |
(48.00%)
|
|
(17.00%)
|
|
| Farxiga | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 694
|
|
$ 1,618
|
|
| Actual %, year-on-year |
(19.00%)
|
|
(6.00%)
|
|
| CER %, year-on-year |
(24.00%)
|
|
(13.00%)
|
|
| Farxiga | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 808
|
|
$ 1,586
|
|
| Actual %, year-on-year |
6.00%
|
|
10.00%
|
|
| CER %, year-on-year |
1.00%
|
|
1.00%
|
|
| Farxiga | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 83
|
|
$ 125
|
|
| Actual %, year-on-year |
(22.00%)
|
|
(45.00%)
|
|
| CER %, year-on-year |
(19.00%)
|
|
(45.00%)
|
|
| Crestor |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 331
|
|
$ 685
|
|
| Actual %, year-on-year |
4.00%
|
|
8.00%
|
|
| CER %, year-on-year |
1.00%
|
|
4.00%
|
|
| Crestor | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 10
|
|
$ 18
|
|
| Actual %, year-on-year |
(18.00%)
|
|
(23.00%)
|
|
| Crestor | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 299
|
|
$ 612
|
|
| Actual %, year-on-year |
9.00%
|
|
12.00%
|
|
| CER %, year-on-year |
5.00%
|
|
8.00%
|
|
| Crestor | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
|
|
$ 1
|
|
| CER %, year-on-year |
|
|
80.00%
|
|
| Crestor | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 22
|
|
$ 54
|
|
| Actual %, year-on-year |
(31.00%)
|
|
(16.00%)
|
|
| CER %, year-on-year |
(27.00%)
|
|
(13.00%)
|
|
| Brilinta |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 80
|
|
$ 186
|
|
| Actual %, year-on-year |
(62.00%)
|
|
(64.00%)
|
|
| CER %, year-on-year |
(63.00%)
|
|
(66.00%)
|
|
| Brilinta | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 2
|
|
$ 16
|
|
| Actual %, year-on-year |
(98.00%)
|
|
(94.00%)
|
|
| Brilinta | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 66
|
|
$ 142
|
|
| Actual %, year-on-year |
5.00%
|
|
4.00%
|
|
| CER %, year-on-year |
3.00%
|
|
|
|
| Brilinta | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 11
|
|
$ 24
|
|
| Actual %, year-on-year |
(79.00%)
|
|
(78.00%)
|
|
| CER %, year-on-year |
(80.00%)
|
|
(80.00%)
|
|
| Brilinta | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1
|
|
$ 4
|
|
| Actual %, year-on-year |
(31.00%)
|
|
(35.00%)
|
|
| CER %, year-on-year |
(17.00%)
|
|
(33.00%)
|
|
| Lokelma |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 221
|
|
$ 419
|
|
| Actual %, year-on-year |
26.00%
|
|
28.00%
|
|
| CER %, year-on-year |
26.00%
|
|
26.00%
|
|
| Lokelma | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 85
|
|
$ 164
|
|
| Actual %, year-on-year |
13.00%
|
|
14.00%
|
|
| Lokelma | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 48
|
|
$ 93
|
|
| Actual %, year-on-year |
47.00%
|
|
47.00%
|
|
| CER %, year-on-year |
40.00%
|
|
41.00%
|
|
| Lokelma | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 47
|
|
$ 87
|
|
| Actual %, year-on-year |
54.00%
|
|
56.00%
|
|
| CER %, year-on-year |
46.00%
|
|
44.00%
|
|
| Lokelma | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 41
|
|
$ 75
|
|
| Actual %, year-on-year |
12.00%
|
|
17.00%
|
|
| CER %, year-on-year |
22.00%
|
|
23.00%
|
|
| Seloken |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 157
|
|
$ 337
|
|
| Actual %, year-on-year |
6.00%
|
|
9.00%
|
|
| CER %, year-on-year |
2.00%
|
|
5.00%
|
|
| Seloken | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 153
|
|
$ 326
|
|
| Actual %, year-on-year |
6.00%
|
|
9.00%
|
|
| CER %, year-on-year |
2.00%
|
|
5.00%
|
|
| Seloken | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 3
|
|
$ 9
|
|
| Actual %, year-on-year |
(1.00%)
|
|
5.00%
|
|
| CER %, year-on-year |
(3.00%)
|
|
5.00%
|
|
| Seloken | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1
|
|
$ 2
|
|
| Actual %, year-on-year |
12.00%
|
|
(1.00%)
|
|
| CER %, year-on-year |
4.00%
|
|
(8.00%)
|
|
| roxadustat |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 14
|
|
$ 57
|
|
| Actual %, year-on-year |
(81.00%)
|
|
(62.00%)
|
|
| CER %, year-on-year |
(82.00%)
|
|
(64.00%)
|
|
| roxadustat | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 14
|
|
$ 57
|
|
| Actual %, year-on-year |
(81.00%)
|
|
(62.00%)
|
|
| CER %, year-on-year |
(82.00%)
|
|
(64.00%)
|
|
| Wainua |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 70
|
|
$ 121
|
|
| Actual %, year-on-year |
58.00%
|
|
44.00%
|
|
| CER %, year-on-year |
58.00%
|
|
44.00%
|
|
| Wainua | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 64
|
|
$ 109
|
|
| Actual %, year-on-year |
50.00%
|
|
33.00%
|
|
| Wainua | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1
|
|
$ 4
|
|
| Wainua | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
4
|
|
7
|
|
| Wainua | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
1
|
|
1
|
|
| Baxfendy |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
3
|
|
3
|
|
| Baxfendy | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
2
|
|
2
|
|
| Baxfendy | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
1
|
|
1
|
|
| Other CVRM |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 91
|
|
$ 206
|
|
| Actual %, year-on-year |
(34.00%)
|
|
(25.00%)
|
|
| CER %, year-on-year |
(35.00%)
|
|
(28.00%)
|
|
| Other CVRM | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product sales net of reversals |
$ (7)
|
|
$ (9)
|
|
| Other CVRM | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 70
|
|
$ 145
|
|
| Actual %, year-on-year |
5.00%
|
|
5.00%
|
|
| CER %, year-on-year |
2.00%
|
|
1.00%
|
|
| Other CVRM | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 14
|
|
$ 42
|
|
| Actual %, year-on-year |
(64.00%)
|
|
(45.00%)
|
|
| CER %, year-on-year |
(64.00%)
|
|
(49.00%)
|
|
| Other CVRM | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 14
|
|
$ 28
|
|
| Actual %, year-on-year |
(20.00%)
|
|
(14.00%)
|
|
| CER %, year-on-year |
(14.00%)
|
|
(11.00%)
|
|
| BioPharmaceuticals: total Respiratory & Immunology |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 2,207
|
|
$ 4,357
|
|
| Actual %, year-on-year |
11.00%
|
|
11.00%
|
|
| CER %, year-on-year |
9.00%
|
|
8.00%
|
|
| BioPharmaceuticals: total Respiratory & Immunology | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 982
|
|
$ 1,862
|
|
| Actual %, year-on-year |
|
|
1.00%
|
|
| BioPharmaceuticals: total Respiratory & Immunology | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 490
|
|
$ 1,055
|
|
| Actual %, year-on-year |
29.00%
|
|
16.00%
|
|
| CER %, year-on-year |
24.00%
|
|
11.00%
|
|
| BioPharmaceuticals: total Respiratory & Immunology | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 509
|
|
$ 1,007
|
|
| Actual %, year-on-year |
21.00%
|
|
26.00%
|
|
| CER %, year-on-year |
16.00%
|
|
17.00%
|
|
| BioPharmaceuticals: total Respiratory & Immunology | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 226
|
|
$ 433
|
|
| Actual %, year-on-year |
9.00%
|
|
13.00%
|
|
| CER %, year-on-year |
11.00%
|
|
13.00%
|
|
| Symbicort |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 671
|
|
$ 1,418
|
|
| Actual %, year-on-year |
(6.00%)
|
|
(1.00%)
|
|
| CER %, year-on-year |
(8.00%)
|
|
(4.00%)
|
|
| Symbicort | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 254
|
|
$ 545
|
|
| Actual %, year-on-year |
(20.00%)
|
|
(9.00%)
|
|
| Symbicort | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 191
|
|
$ 417
|
|
| Actual %, year-on-year |
14.00%
|
|
4.00%
|
|
| CER %, year-on-year |
10.00%
|
|
|
|
| Symbicort | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 145
|
|
$ 296
|
|
| Actual %, year-on-year |
6.00%
|
|
9.00%
|
|
| CER %, year-on-year |
2.00%
|
|
1.00%
|
|
| Symbicort | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 81
|
|
$ 160
|
|
| Actual %, year-on-year |
(12.00%)
|
|
(5.00%)
|
|
| CER %, year-on-year |
(14.00%)
|
|
(8.00%)
|
|
| Fasenra |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 570
|
|
$ 1,053
|
|
| Actual %, year-on-year |
14.00%
|
|
14.00%
|
|
| CER %, year-on-year |
13.00%
|
|
12.00%
|
|
| Fasenra | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 338
|
|
$ 594
|
|
| Actual %, year-on-year |
10.00%
|
|
7.00%
|
|
| Fasenra | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 46
|
|
$ 92
|
|
| Actual %, year-on-year |
81.00%
|
|
75.00%
|
|
| CER %, year-on-year |
75.00%
|
|
69.00%
|
|
| Fasenra | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 129
|
|
$ 258
|
|
| Actual %, year-on-year |
3.00%
|
|
13.00%
|
|
| CER %, year-on-year |
(1.00%)
|
|
4.00%
|
|
| Fasenra | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 57
|
|
$ 109
|
|
| Actual %, year-on-year |
29.00%
|
|
31.00%
|
|
| CER %, year-on-year |
34.00%
|
|
33.00%
|
|
| Breztri |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 346
|
|
$ 699
|
|
| Actual %, year-on-year |
22.00%
|
|
20.00%
|
|
| CER %, year-on-year |
20.00%
|
|
17.00%
|
|
| Breztri | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 161
|
|
$ 309
|
|
| Actual %, year-on-year |
9.00%
|
|
5.00%
|
|
| Breztri | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 93
|
|
$ 208
|
|
| Actual %, year-on-year |
43.00%
|
|
34.00%
|
|
| CER %, year-on-year |
35.00%
|
|
27.00%
|
|
| Breztri | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 62
|
|
$ 127
|
|
| Actual %, year-on-year |
36.00%
|
|
45.00%
|
|
| CER %, year-on-year |
31.00%
|
|
34.00%
|
|
| Breztri | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 30
|
|
$ 55
|
|
| Actual %, year-on-year |
23.00%
|
|
24.00%
|
|
| CER %, year-on-year |
26.00%
|
|
24.00%
|
|
| Tezspire |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 172
|
|
$ 321
|
|
| Actual %, year-on-year |
54.00%
|
|
62.00%
|
|
| CER %, year-on-year |
51.00%
|
|
54.00%
|
|
| Tezspire | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 24
|
|
$ 44
|
|
| Tezspire | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 107
|
|
$ 202
|
|
| Actual %, year-on-year |
49.00%
|
|
57.00%
|
|
| CER %, year-on-year |
42.00%
|
|
46.00%
|
|
| Tezspire | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 41
|
|
$ 75
|
|
| Actual %, year-on-year |
33.00%
|
|
39.00%
|
|
| CER %, year-on-year |
41.00%
|
|
43.00%
|
|
| Saphnelo |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 209
|
|
$ 380
|
|
| Actual %, year-on-year |
25.00%
|
|
25.00%
|
|
| CER %, year-on-year |
24.00%
|
|
24.00%
|
|
| Saphnelo | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 175
|
|
$ 318
|
|
| Actual %, year-on-year |
21.00%
|
|
20.00%
|
|
| Saphnelo | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 7
|
|
$ 11
|
|
| Actual %, year-on-year |
68.00%
|
|
67.00%
|
|
| CER %, year-on-year |
64.00%
|
|
63.00%
|
|
| Saphnelo | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 19
|
|
$ 36
|
|
| Actual %, year-on-year |
58.00%
|
|
71.00%
|
|
| CER %, year-on-year |
51.00%
|
|
57.00%
|
|
| Saphnelo | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 8
|
|
$ 15
|
|
| Actual %, year-on-year |
31.00%
|
|
40.00%
|
|
| CER %, year-on-year |
38.00%
|
|
44.00%
|
|
| Pulmicort |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 120
|
|
$ 269
|
|
| Actual %, year-on-year |
13.00%
|
|
2.00%
|
|
| CER %, year-on-year |
9.00%
|
|
(3.00%)
|
|
| Pulmicort | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 2
|
|
$ 3
|
|
| Actual %, year-on-year |
11.00%
|
|
(6.00%)
|
|
| Pulmicort | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 97
|
|
$ 219
|
|
| Actual %, year-on-year |
20.00%
|
|
5.00%
|
|
| CER %, year-on-year |
15.00%
|
|
|
|
| Pulmicort | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 14
|
|
$ 31
|
|
| Actual %, year-on-year |
(5.00%)
|
|
(9.00%)
|
|
| CER %, year-on-year |
(9.00%)
|
|
(16.00%)
|
|
| Pulmicort | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 7
|
|
$ 16
|
|
| Actual %, year-on-year |
(17.00%)
|
|
(16.00%)
|
|
| CER %, year-on-year |
(17.00%)
|
|
(17.00%)
|
|
| Airsupra |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 50
|
|
$ 87
|
|
| Actual %, year-on-year |
19.00%
|
|
24.00%
|
|
| CER %, year-on-year |
18.00%
|
|
23.00%
|
|
| Airsupra | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 45
|
|
$ 78
|
|
| Actual %, year-on-year |
9.00%
|
|
12.00%
|
|
| Airsupra | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 5
|
|
$ 9
|
|
| Other R&I |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 69
|
|
$ 130
|
|
| Actual %, year-on-year |
13.00%
|
|
(18.00%)
|
|
| CER %, year-on-year |
9.00%
|
|
(21.00%)
|
|
| Other R&I | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 7
|
|
$ 15
|
|
| Actual %, year-on-year |
(55.00%)
|
|
(73.00%)
|
|
| Other R&I | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 27
|
|
$ 55
|
|
| Actual %, year-on-year |
(1.00%)
|
|
(22.00%)
|
|
| CER %, year-on-year |
(8.00%)
|
|
(26.00%)
|
|
| Other R&I | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 33
|
|
$ 57
|
|
| Actual %, year-on-year |
|
|
97.00%
|
|
| CER %, year-on-year |
|
|
88.00%
|
|
| Other R&I | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 2
|
|
$ 3
|
|
| Actual %, year-on-year |
6.00%
|
|
(1.00%)
|
|
| CER %, year-on-year |
5.00%
|
|
(4.00%)
|
|
| Beyfortus |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 47
|
|
$ 71
|
|
| Actual %, year-on-year |
(52.00%)
|
|
(44.00%)
|
|
| CER %, year-on-year |
(52.00%)
|
|
(44.00%)
|
|
| Beyfortus | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 38
|
|
$ 61
|
|
| Actual %, year-on-year |
(49.00%)
|
|
(40.00%)
|
|
| Beyfortus | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 8
|
|
$ 9
|
|
| Actual %, year-on-year |
(66.00%)
|
|
(62.00%)
|
|
| CER %, year-on-year |
(67.00%)
|
|
(63.00%)
|
|
| Beyfortus | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1
|
|
$ 1
|
|
| Actual %, year-on-year |
34.00%
|
|
(38.00%)
|
|
| CER %, year-on-year |
58.00%
|
|
(29.00%)
|
|
| FluMist |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 18
|
|
$ 26
|
|
| Actual %, year-on-year |
79.00%
|
|
|
|
| CER %, year-on-year |
78.00%
|
|
|
|
| FluMist | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product sales net of reversals |
$ (2)
|
|
(2)
|
|
| FluMist | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
1
|
|
1
|
|
| FluMist | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 19
|
|
27
|
|
| Actual %, year-on-year |
90.00%
|
|
|
|
| CER %, year-on-year |
82.00%
|
|
|
|
| Total rare diseases |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 2,490
|
|
$ 4,911
|
|
| Actual %, year-on-year |
9.00%
|
|
13.00%
|
|
| CER %, year-on-year |
8.00%
|
|
11.00%
|
|
| Total rare diseases | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,452
|
|
$ 2,823
|
|
| Actual %, year-on-year |
8.00%
|
|
9.00%
|
|
| Total rare diseases | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 305
|
|
$ 652
|
|
| Actual %, year-on-year |
10.00%
|
|
35.00%
|
|
| CER %, year-on-year |
6.00%
|
|
28.00%
|
|
| Total rare diseases | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 442
|
|
$ 874
|
|
| Actual %, year-on-year |
7.00%
|
|
13.00%
|
|
| CER %, year-on-year |
3.00%
|
|
4.00%
|
|
| Total rare diseases | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 291
|
|
$ 562
|
|
| Actual %, year-on-year |
13.00%
|
|
13.00%
|
|
| CER %, year-on-year |
20.00%
|
|
16.00%
|
|
| Ultomiris |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,314
|
|
$ 2,584
|
|
| Actual %, year-on-year |
12.00%
|
|
16.00%
|
|
| CER %, year-on-year |
12.00%
|
|
14.00%
|
|
| Ultomiris | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 719
|
|
$ 1,398
|
|
| Actual %, year-on-year |
8.00%
|
|
10.00%
|
|
| Ultomiris | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 87
|
|
$ 190
|
|
| Actual %, year-on-year |
42.00%
|
|
68.00%
|
|
| CER %, year-on-year |
41.00%
|
|
65.00%
|
|
| Ultomiris | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 307
|
|
$ 605
|
|
| Actual %, year-on-year |
14.00%
|
|
22.00%
|
|
| CER %, year-on-year |
9.00%
|
|
12.00%
|
|
| Ultomiris | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 201
|
|
$ 391
|
|
| Actual %, year-on-year |
12.00%
|
|
13.00%
|
|
| CER %, year-on-year |
19.00%
|
|
17.00%
|
|
| Soliris |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 389
|
|
$ 778
|
|
| Actual %, year-on-year |
(27.00%)
|
|
(20.00%)
|
|
| CER %, year-on-year |
(28.00%)
|
|
(22.00%)
|
|
| Soliris | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 199
|
|
$ 414
|
|
| Actual %, year-on-year |
(29.00%)
|
|
(27.00%)
|
|
| Soliris | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 135
|
|
$ 248
|
|
| Actual %, year-on-year |
(15.00%)
|
|
10.00%
|
|
| CER %, year-on-year |
(19.00%)
|
|
6.00%
|
|
| Soliris | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 28
|
|
$ 61
|
|
| Actual %, year-on-year |
(50.00%)
|
|
(46.00%)
|
|
| CER %, year-on-year |
(50.00%)
|
|
(50.00%)
|
|
| Soliris | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 27
|
|
$ 55
|
|
| Actual %, year-on-year |
(21.00%)
|
|
(20.00%)
|
|
| CER %, year-on-year |
(22.00%)
|
|
(21.00%)
|
|
| Strensiq |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 536
|
|
$ 1,053
|
|
| Actual %, year-on-year |
36.00%
|
|
41.00%
|
|
| CER %, year-on-year |
36.00%
|
|
40.00%
|
|
| Strensiq | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 452
|
|
$ 859
|
|
| Actual %, year-on-year |
42.00%
|
|
47.00%
|
|
| Strensiq | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 16
|
|
$ 65
|
|
| Actual %, year-on-year |
2.00%
|
|
30.00%
|
|
| CER %, year-on-year |
2.00%
|
|
13.00%
|
|
| Strensiq | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 37
|
|
$ 68
|
|
| Actual %, year-on-year |
20.00%
|
|
20.00%
|
|
| CER %, year-on-year |
14.00%
|
|
10.00%
|
|
| Strensiq | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 31
|
|
$ 61
|
|
| Actual %, year-on-year |
7.00%
|
|
10.00%
|
|
| CER %, year-on-year |
15.00%
|
|
14.00%
|
|
| Koselugo |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 177
|
|
$ 347
|
|
| Actual %, year-on-year |
29.00%
|
|
26.00%
|
|
| CER %, year-on-year |
27.00%
|
|
21.00%
|
|
| Koselugo | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 52
|
|
$ 94
|
|
| Actual %, year-on-year |
|
|
(11.00%)
|
|
| Koselugo | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 54
|
|
$ 115
|
|
| Actual %, year-on-year |
51.00%
|
|
52.00%
|
|
| CER %, year-on-year |
45.00%
|
|
42.00%
|
|
| Koselugo | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 50
|
|
$ 99
|
|
| Actual %, year-on-year |
34.00%
|
|
39.00%
|
|
| CER %, year-on-year |
27.00%
|
|
28.00%
|
|
| Koselugo | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 21
|
|
$ 39
|
|
| Actual %, year-on-year |
78.00%
|
|
74.00%
|
|
| CER %, year-on-year |
90.00%
|
|
80.00%
|
|
| Other Rare Disease |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 74
|
|
$ 149
|
|
| Actual %, year-on-year |
36.00%
|
|
32.00%
|
|
| CER %, year-on-year |
33.00%
|
|
25.00%
|
|
| Other Rare Disease | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 30
|
|
$ 58
|
|
| Actual %, year-on-year |
8.00%
|
|
7.00%
|
|
| Other Rare Disease | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 13
|
|
$ 34
|
|
| Actual %, year-on-year |
|
|
73.00%
|
|
| CER %, year-on-year |
|
|
47.00%
|
|
| Other Rare Disease | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 20
|
|
$ 41
|
|
| Actual %, year-on-year |
11.00%
|
|
20.00%
|
|
| CER %, year-on-year |
5.00%
|
|
10.00%
|
|
| Other Rare Disease | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 11
|
|
$ 16
|
|
| Total Other medicines |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 230
|
|
$ 480
|
|
| Actual %, year-on-year |
(4.00%)
|
|
(6.00%)
|
|
| CER %, year-on-year |
(6.00%)
|
|
(8.00%)
|
|
| Total Other medicines | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 19
|
|
$ 42
|
|
| Actual %, year-on-year |
(9.00%)
|
|
6.00%
|
|
| Total Other medicines | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 166
|
|
$ 359
|
|
| Actual %, year-on-year |
(10.00%)
|
|
(9.00%)
|
|
| CER %, year-on-year |
(13.00%)
|
|
(11.00%)
|
|
| Total Other medicines | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 25
|
|
$ 39
|
|
| Actual %, year-on-year |
52.00%
|
|
12.00%
|
|
| CER %, year-on-year |
51.00%
|
|
8.00%
|
|
| Total Other medicines | Established RoW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 20
|
|
$ 40
|
|
| Actual %, year-on-year |
12.00%
|
|
(3.00%)
|
|
| CER %, year-on-year |
14.00%
|
|
(3.00%)
|
|